Establishment of Stable Knockdown of MACC1 Oncogene in Patient-Derived Ovarian Cancer Organoids
Methods and Protocols · 20.12.2024 · 7 (6) · 104
DOI: 10.3390/mps7060104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Methods and Protocols, online erschienen am 20.12.2024. Verfasst von Sophia Hierlmayer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, 81377 Munich, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Aid, BMBF, ERAPERMED2022-141.
Abstract (Originalsprache)
High-grade serous ovarian cancer (HGSOC) remains the most lethal gynecological malignancy, and there is still an unmet medical need to deepen basic research on its origins and mechanisms of progression. Patient-derived organoids of high-grade serous ovarian cancer (HGSOC-PDO) are a powerful model to study the complexity of ovarian cancer as they maintain, in vitro, the mutational profile and cellular architecture of the cancer tissue. Genetic modifications by lentiviral transduction allow novel insights into signaling pathways and the potential identification of biomarkers regarding the evolution of drug resistance. Here, we provide an in-depth and detailed protocol to successfully modify the gene expression of HGSOC-PDOs by lentiviral transduction. As an example, we validate our protocol and create a stable knockdown of the MACC1 oncogene with an efficacy of ≥72% in two HGSOC-PDO lines, which remained stable for >3 months in culture. Moreover, we explain step-by-step the sample preparation for the validation procedures on transcriptional (qPCR) and protein (Western Blot) levels. Sustained downregulation of specific genes by lentiviral transduction enables the analysis of the resulting phenotypic and morphological changes. It serves as a valuable in-vitro model to study the mechanisms of ovarian cancer pathogenesis and allows for the evaluation of therapeutic approaches.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, 81377 Munich, Germany.
- Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany.
- Department of Pediatrics, Dr. Von Hauner Children's Hospital, University Hospital, Ludwig Maximilians University Munich, 80337 Munich, Germany.
- German Cancer Consortium, DKTK, Partner Site Munich, 69120 Heidelberg, Germany.
ORCID-Profile: Fabian Trillsch, Mirjana Kessler
Förderung
- German Cancer Aid
- BMBF
- ERAPERMED2022-141
- LMU Medical & Clinician Scientist Program
- German Cancer Research Center DKTK
Zitieren
APA
Hierlmayer, S., Hladchenko, L., Reichenbach, J., Klein, C., Mahner, S., Trillsch, F., Kessler, M., & Chelariu-Raicu, A. (2024). Establishment of Stable Knockdown of MACC1 Oncogene in Patient-Derived Ovarian Cancer Organoids. Methods and Protocols, 7(6), 104. https://doi.org/10.3390/mps7060104
Vancouver
Hierlmayer S, Hladchenko L, Reichenbach J, Klein C, Mahner S, Trillsch F, et al. Establishment of Stable Knockdown of MACC1 Oncogene in Patient-Derived Ovarian Cancer Organoids. Methods and Protocols. 2024;7(6):104. doi:10.3390/mps7060104
BibTeX
@article{Hierlmayer2024,
author = {Hierlmayer, Sophia and Hladchenko, Liliia and Reichenbach, Juliane and Klein, Christoph and Mahner, Sven and Trillsch, Fabian and Kessler, Mirjana and Chelariu-Raicu, Anca},
title = {Establishment of Stable Knockdown of MACC1 Oncogene in Patient-Derived Ovarian Cancer Organoids},
journal = {Methods and Protocols},
year = {2024},
volume = {7},
number = {6},
pages = {104},
doi = {10.3390/mps7060104}
}
EUVIMED